Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 1,212 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 1,212 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total value of $25,488.36. Following the completion of the sale, the general counsel now owns 119,791 shares in the company, valued at approximately $2,519,204.73. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phreesia Trading Down 2.2 %

NYSE:PHR opened at $20.40 on Friday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.40 and a beta of 0.93. Phreesia, Inc. has a 52 week low of $12.05 and a 52 week high of $29.16. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average of $23.36 and a 200 day moving average of $22.44.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. The business had revenue of $102.12 million for the quarter, compared to the consensus estimate of $101.76 million. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. As a group, sell-side analysts anticipate that Phreesia, Inc. will post -1.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on PHR. KeyCorp cut their price target on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Truist Financial raised their target price on shares of Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. Royal Bank of Canada reissued a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research note on Friday, September 27th. JMP Securities reissued a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Finally, Robert W. Baird upped their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.42.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC grew its stake in shares of Phreesia by 76.5% during the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after acquiring an additional 1,300 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Phreesia in the 1st quarter worth approximately $169,000. Quadrature Capital Ltd purchased a new stake in Phreesia during the 1st quarter worth approximately $202,000. Lombard Odier Asset Management USA Corp purchased a new stake in Phreesia during the 2nd quarter worth approximately $202,000. Finally, Point72 DIFC Ltd acquired a new position in Phreesia during the 2nd quarter valued at approximately $209,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.